BioSpace News Archive

In the near future, painful jabs and muscle soreness that persists for days could be replaced by new immunization approaches including intradermal delivery, edible and intranasal vaccines.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the third quarter of 2022 before the U.S. market opens on November 16, 2022.

Sequana Medical NV announces positive top-line results from the North American pivotal POSEIDON study of the alfapump, a fully implantable, wirelessly charged, breakthrough device for the treatment of recurrent or refractory ascites due to liver cirrhosis.

RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Form F-6 registration statement for depositary shares evidenced by American Depositary Receipt with the U.S. Securities and Exchange Commission.

avateramedical GmbH, an innovative German medical technology company specializing in robot-assisted, minimally invasive surgery, is pleased to announce that its avatera system, which is in clinical use at several clinics across Europe, has successfully completed its first live surgery during the annual meeting of the German Society for Robot-Assisted Urology.

Dutch/Swiss biotech company Micreos announced it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

Centene Corporation announced its financial results for the third quarter ended September 30, 2022.

Caris Life Sciences® announced that Virginia Commonwealth University Massey Cancer Center has joined Caris’ Precision Oncology Alliance™.

BerGenBio ASA and Meteva AS announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.